搜索
Shattuck Labs Inc
STTK添加自选
6.260USD
-0.410-6.15%
收盘 05/15, 16:00（美东）报价延迟15分钟
473.14M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-6.15%
5天
-8.61%
1月
-14.83%
6月
+232.98%
今年开始到现在
+71.51%
1年
+469.09%
TradingKey Shattuck Labs Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Shattuck Labs Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名89/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价13.00。中期看，股价处于上升通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Shattuck Labs Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Shattuck Labs Inc亮点
亮点风险
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
业绩增长期
公司处于发展阶段，最新年度总收入1.00M美元
估值低估
公司最新PE估值-11.10，处于3年历史低位
机构加仓
最新机构持股50.41M股，环比增加16.19%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值36.93K
分析师目标
根据
8
位分析师
买入
评级
13.000
目标均价
+94.90%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Shattuck Labs Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Shattuck Labs Inc简介
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
公司代码STTK
公司Shattuck Labs Inc
CEOSchreiber (Taylor)
网址https://www.shattucklabs.com/
相关品种
